Annual Accounts Receivable
$4.75 B
-$315.27 M-6.23%
March 31, 2024
Summary
- As of February 7, 2025, TAK annual accounts receivable is $4.75 billion, with the most recent change of -$315.27 million (-6.23%) on March 31, 2024.
- During the last 3 years, TAK annual accounts receivable has fallen by -$2.40 billion (-33.55%).
- TAK annual accounts receivable is now -33.55% below its all-time high of $7.15 billion, reached on March 31, 2021.
Performance
TAK Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$4.53 B
-$374.85 M-7.64%
December 1, 2024
Summary
- As of February 7, 2025, TAK quarterly accounts receivable is $4.53 billion, with the most recent change of -$374.85 million (-7.64%) on December 1, 2024.
- Over the past year, TAK quarterly accounts receivable has dropped by -$374.85 million (-7.64%).
- TAK quarterly accounts receivable is now -40.97% below its all-time high of $7.67 billion, reached on December 31, 2020.
Performance
TAK Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
TAK Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -6.2% | -7.6% |
| 3 y3 years | -33.5% | -10.5% |
| 5 y5 years | -24.6% | -36.6% |
TAK Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -33.5% | at low | -27.1% | at low |
| 5 y | 5-year | -33.5% | at low | -41.0% | at low |
| alltime | all time | -33.5% | +258.5% | -41.0% | +34.3% |
Takeda Pharmaceutical Company Limited Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | - | $4.53 B(-7.6%) |
| Sep 2024 | - | $4.91 B(+4.5%) |
| Jun 2024 | - | $4.69 B(-1.1%) |
| Mar 2024 | $4.75 B(-6.2%) | $4.75 B(-6.5%) |
| Dec 2023 | - | $5.08 B(+0.4%) |
| Sep 2023 | - | $5.06 B(-7.7%) |
| Jun 2023 | - | $5.48 B(+8.1%) |
| Mar 2023 | $5.06 B(-13.0%) | $5.06 B(-6.1%) |
| Dec 2022 | - | $5.39 B(+2.6%) |
| Sep 2022 | - | $5.26 B(-5.7%) |
| Jun 2022 | - | $5.58 B(-4.1%) |
| Mar 2022 | $5.82 B(-18.6%) | $5.82 B(-6.4%) |
| Dec 2021 | - | $6.22 B(-17.5%) |
| Sep 2021 | - | $7.54 B(+0.7%) |
| Jun 2021 | - | $7.48 B(+4.7%) |
| Mar 2021 | $7.15 B(+8.0%) | $7.15 B(-6.9%) |
| Dec 2020 | - | $7.67 B(+7.6%) |
| Sep 2020 | - | $7.13 B(-2.2%) |
| Jun 2020 | - | $7.29 B(+10.2%) |
| Mar 2020 | $6.62 B(+5.0%) | $6.62 B(-12.2%) |
| Dec 2019 | - | $7.54 B(+4.4%) |
| Sep 2019 | - | $7.22 B(+2.5%) |
| Jun 2019 | - | $7.05 B(+11.8%) |
| Mar 2019 | $6.30 B(+81.1%) | $6.30 B(+36.5%) |
| Dec 2018 | - | $4.62 B(+13.8%) |
| Sep 2018 | - | $4.06 B(-0.5%) |
| Jun 2018 | - | $4.08 B(+17.3%) |
| Mar 2018 | $3.48 B | $3.48 B(-23.4%) |
| Dec 2017 | - | $4.54 B(+9.5%) |
| Sep 2017 | - | $4.15 B(+4.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2017 | - | $3.97 B(+4.9%) |
| Mar 2017 | $3.79 B(+2.5%) | $3.79 B(-10.2%) |
| Dec 2016 | - | $4.22 B(-2.2%) |
| Sep 2016 | - | $4.31 B(+3.9%) |
| Jun 2016 | - | $4.15 B(+12.3%) |
| Mar 2016 | $3.70 B(-0.2%) | $3.70 B(-8.0%) |
| Dec 2015 | - | $4.02 B(+2.1%) |
| Sep 2015 | - | $3.94 B(+4.7%) |
| Jun 2015 | - | $3.76 B(+1.5%) |
| Mar 2015 | $3.70 B(-11.5%) | $3.70 B(-9.5%) |
| Dec 2014 | - | $4.09 B(-1.6%) |
| Sep 2014 | - | $4.16 B(-0.7%) |
| Jun 2014 | - | $4.19 B(+0.2%) |
| Mar 2014 | $4.18 B(+5.1%) | $4.18 B(+2.6%) |
| Dec 2013 | - | $4.08 B(+3.4%) |
| Sep 2013 | - | $3.94 B(+5.8%) |
| Jun 2013 | - | $3.73 B(-6.4%) |
| Mar 2013 | $3.98 B(-8.2%) | $3.98 B(-10.0%) |
| Dec 2012 | - | $4.42 B(+2.7%) |
| Sep 2012 | - | $4.31 B(-0.8%) |
| Mar 2012 | $4.34 B(+28.6%) | $4.34 B(+28.6%) |
| Mar 2011 | $3.37 B(+71.4%) | $3.37 B(-10.5%) |
| Dec 2008 | - | $3.77 B |
| Mar 2007 | $1.97 B(+11.7%) | - |
| Mar 2006 | $1.76 B(-4.1%) | - |
| Mar 2005 | $1.84 B(+7.0%) | - |
| Mar 2004 | $1.72 B(+20.4%) | - |
| Mar 2003 | $1.43 B(+7.6%) | - |
| Mar 2002 | $1.32 B(-12.7%) | - |
| Mar 2001 | $1.52 B | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual accounts receivable?
- What is the all time high annual accounts receivable for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual accounts receivable year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly accounts receivable year-on-year change?
What is Takeda Pharmaceutical Company Limited annual accounts receivable?
The current annual accounts receivable of TAK is $4.75 B
What is the all time high annual accounts receivable for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual accounts receivable is $7.15 B
What is Takeda Pharmaceutical Company Limited annual accounts receivable year-on-year change?
Over the past year, TAK annual accounts receivable has changed by -$315.27 M (-6.23%)
What is Takeda Pharmaceutical Company Limited quarterly accounts receivable?
The current quarterly accounts receivable of TAK is $4.53 B
What is the all time high quarterly accounts receivable for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly accounts receivable is $7.67 B
What is Takeda Pharmaceutical Company Limited quarterly accounts receivable year-on-year change?
Over the past year, TAK quarterly accounts receivable has changed by -$374.85 M (-7.64%)